Immune Response Features in Allergic Airway Diseases

NCT ID: NCT04352088

Last Updated: 2020-04-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-01

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate immune mechanisms and phenotypes and endotypes of allergic airway diseases - allergic rhinitis and allergic asthma. Pathogenesis of these diseases are not fully investigated yet. Patients with the same disease have different dominant symptoms, course of the disease and response to treatment. Moreover, there is a hypothesis about united airway disease suggesting that allergic rhinitis and allergic asthma is different manifestation of the same disease. This led to assumption of phenotypes and endotypes. This classification which still is not unified can let to prescribe personalized treatment for every patient.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Rhinitis Allergic Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Allergic rhinitis patients

Nasal provocation test

Intervention Type PROCEDURE

Allergen extract under controlled conditions will be applied into nasal mucous.

Allergic rhinitis and asthma patients

Nasal provocation test

Intervention Type PROCEDURE

Allergen extract under controlled conditions will be applied into nasal mucous.

Healthy individuals

Nasal provocation test

Intervention Type PROCEDURE

Allergen extract under controlled conditions will be applied into nasal mucous.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nasal provocation test

Allergen extract under controlled conditions will be applied into nasal mucous.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypersensitivity to house dust mites
* Allergic rhinitis with or without mild to moderate asthma

Exclusion Criteria

* Acute or chronic infections
* Use of systemic immunosupresants (wait 1 month)
* Use of systemic or local antihistamines (wait 1 week)
* Use of intranasal steroids (wait 1 month)
* Oncological or active autoimmune diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lithuanian University of Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Brigita Sitkauskiene

Prof., Head of Department of Immunology and Allergology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital of Lithuanian University of Health Sciences Kauno klinikos

Kaunas, , Lithuania

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Lithuania

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laura Tamasauskiene, MD

Role: CONTACT

+37061569127

Brigita Sitkauskiene

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tomas Lapinskas, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AKTL1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.